share_log

Piper Sandler Downgrades Eagle Pharmaceuticals to Underweight, Lowers Price Target to $17

Piper Sandler Downgrades Eagle Pharmaceuticals to Underweight, Lowers Price Target to $17

派杰投资将eagle制药评级下调至低于平均水平,将目标股价下调至17美元。
Benzinga ·  2023/08/09 12:12

Piper Sandler analyst David Amsellem downgrades Eagle Pharmaceuticals (NASDAQ:EGRX) from Neutral to Underweight and lowers the price target from $26 to $17.

派杰投资分析师David Amsellem将eagle制药(纳斯达克:EGRX)的评级由中立下调至减持,将价值目标从26美元下调至17美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发